# Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension

> **NCT06608472** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 292 (estimated)

## Conditions studied

- Essential Arterial Hypertension

## Interventions

- **DRUG:** N0877
- **DRUG:** Benicar HCT ® Tablets 40 mg/25 mg

## Key facts

- **NCT ID:** NCT06608472
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-11-30
- **Primary completion:** 2028-04-30
- **Final completion:** 2029-10-30
- **Target enrollment:** 292 (ESTIMATED)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608472, "Fixed-dose Combination of an Angiotensin Receptor Blocker and Thiazide Diuretic for Essential Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06608472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*